Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation
Authors
Keywords
Atrial Fibrillation, Warfarin, Ischemic Stroke, International Normalize Ratio, Dabigatran
Journal
PHARMACOECONOMICS
Volume 33, Issue 3, Pages 271-283
Publisher
Springer Nature
Online
2014-11-21
DOI
10.1007/s40273-014-0236-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry
- (2014) J. Beyer-Westendorf et al. BLOOD
- Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
- (2014) Gregory Y.H. Lip et al. CLINICAL THERAPEUTICS
- The quality of oral anticoagulation in general practice in patients with atrial fibrillation
- (2014) Sabrina Mueller et al. European Journal of Internal Medicine
- Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin
- (2014) T. Lanitis et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
- (2013) James V. Freeman et al. ANNALS OF INTERNAL MEDICINE
- Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation
- (2013) Anuraag R. Kansal et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
- (2013) Carla Rognoni et al. CLINICAL DRUG INVESTIGATION
- Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting
- (2013) Joris Kleintjens et al. PHARMACOECONOMICS
- Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
- (2013) Amanda R. Harrington et al. STROKE
- Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation
- (2013) Doug Coyle et al. VALUE IN HEALTH
- Cost–Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
- (2012) Soyon Lee et al. AMERICAN JOURNAL OF CARDIOLOGY
- 2012 focused update of the ESC Guidelines for the management of atrial fibrillation
- (2012) et al. EUROPEAN HEART JOURNAL
- Computerised assistance for warfarin dosage — Effects on treatment quality
- (2012) Ivar Dimberg et al. European Journal of Internal Medicine
- Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation
- (2012) Anuraag R Kansal et al. HEART
- Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
- (2012) Soyon Lee et al. PLoS One
- An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation
- (2012) Jack Ansell et al. THROMBOSIS AND HAEMOSTASIS
- The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: A nationwide cohort study
- (2012) Christian Torp-Pedersen et al. THROMBOSIS AND HAEMOSTASIS
- Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark
- (2012) Lars K Langkilde et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation
- (2011) Shimoli V. Shah et al. CIRCULATION
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
- (2011) Manesh R. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective
- (2011) Anuraag Kansal et al. THROMBOSIS AND HAEMOSTASIS
- A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation
- (2010) Ron Pisters et al. CHEST
- Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
- (2010) Lars Wallentin et al. LANCET
- Evaluation of costs and outcome in cardioembolic stroke or TIA
- (2009) Yaroslav Winter et al. JOURNAL OF NEUROLOGY
- Major Vascular Events after Transient Ischaemic Attack and Minor Ischaemic Stroke: Post Hoc Modelling of Incidence Dynamics
- (2008) Penka A. Atanassova et al. CEREBROVASCULAR DISEASES
- Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects
- (2008) Dagmar Kubitza et al. CURRENT MEDICAL RESEARCH AND OPINION
- Pharmacoeconomic Concepts in Antiplatelet Therapy: Understanding Cost-Effectiveness Analyses Using Clopidogrel as an Example
- (2008) William S. Weintraub JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- Model-Based Cost-Effectiveness Analyses for the Treatment of Acute Stroke Events: A Review and Summary of Challenges
- (2008) Stephanie R. Earnshaw et al. VALUE IN HEALTH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now